Table of Contents
Off–label prescribing of medicines is prevalent worldwide because it gives freedom to physicians to apply new therapeutic options based on the latest evidence. Although physicians may lawfully prescribe approved Drugs for any use consistent with available scientific data and proper medical practice, but unfortunately, this is done without adequate scientific data. Often, when the best available therapeutic option fails, patients demand new approach or new treatment which ultimately leads to off–label uses.
Off–label use is very common in United States. United States Off–label Drugs demand has grown at a fast pace in the past decade and likely to grow in the forecasting period. It is likely that United States off–label market will cross the figure of 60 Billion by the year 2020. Central Nervous System (CNS) and Cancer off–label Drugs controls the largest market share of the total US off–label Drugs market. Anti–Infectives Off–Label Drugs Market and Anti–Ashmatics Off–Label Drugs together are expected to control close to 35% market share by 2020.
Renub Research study titled “United States Off–Label Drugs Market & Forecast” report provides a comprehensive analysis of the emerging Off–Label Drugs market. The report also entails commonly prescribed Off–Label Drugs, Perspective of Physicians, Patients, Pharmaceutical Companies and Regulatory Authorities, Off–label Promotion Settlements under the False Claims Act. The report also studies Drivers and Challenges of United States Off–Label Drugs market. This 67 page report with 16 Figures and 1 Table studies 6 Off–Label Drugs Segment.
The 6 Off–Label Drugs Segment Covered in the Report are as Follows:
1. Cancer Off–Label Drugs
2. Central Nervous System (CNS) Off–Label Drugs
3. Anti–Ashmatics Off–Label Drugs
4. Anti–Allergies Off–Label Drugs
5. Anti–Hypertensives Off–Label Drugs
6. Anti–Infectives Off–Label Drugs
This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephonic interviews with industry experts.
Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 Summary Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease ...
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...
PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...